The American College of Physicians (ACP) recently published rapid practice points regarding RSV vaccines for adults. Specifically, these points evaluate vaccine efficacy and safety for non-pregnant and non-immunocompromised patients. Consequently, clinicians can now access updated guidance for protecting their geriatric patients. Moreover, the report focuses on the benefits of protein subunit vaccines like Arexvy and Abrysvo.
Strong Recommendations for Adults Aged 75 and Older
The ACP suggests that all adults aged 75 years and older should receive a protein subunit vaccine. Furthermore, clinical trials show that these vaccines significantly reduce hospitalizations in older populations. However, the risk for severe illness remains high for those who do not get immunized. Therefore, clinicians must prioritize vaccination for this specific age group to improve health outcomes.
Using RSV Vaccines for Adults Aged 60 to 74
For adults aged 60 to 74, the practice points recommend a more individualized approach. Specifically, patients with chronic conditions like heart or lung disease may consider receiving the vaccine. Additionally, shared clinical decision-making allows doctors to tailor care to specific patient risks. Consequently, this strategy ensures that those most at risk for severe RSV receive necessary protection.
Clinical Safety and Harms Analysis
Safety data suggests that these vaccines are generally safe for the target population. Nevertheless, clinicians must acknowledge the rare risk of neurological events such as Guillain-Barré syndrome. Contrastingly, the significant reduction in severe respiratory disease usually justifies the vaccine’s use. Therefore, the committee highlights that clinical benefits outweigh potential harms for older seniors.
Frequently Asked Questions
Q1: Who should receive the RSV vaccine according to the new ACP points?
ACP recommends that all adults aged 75 and older receive the vaccine. Additionally, those aged 60 to 74 who are at high risk for severe illness may consider it based on clinical judgment.
Q2: What are the primary benefits of these vaccines?
Specifically, clinical evidence shows that these vaccines reduce the risk of hospitalization and severe lower respiratory tract disease. Furthermore, they provide robust protection against the respiratory syncytial virus in older populations.
References
- Qaseem A et al. Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians. Ann Intern Med. 2026 Mar 03. doi: 10.7326/ANNALS-25-05485. PMID: 41771137.
- CDC. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2024 Aug 15.
- Papi A, Ison MG, Langley JM, et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):595-608.